HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Yoshiki Sawa Hikaru Matsuda Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Memon, I. A. Articles by Matsuda, H. Search for Related Content PubMed PubMed Citation Articles by Memon, I. A. Articles by Matsuda, H.

J Thorac Cardiovasc Surg 2005;130:646-653
© 2005 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Combined autologous cellular cardiomyoplasty with skeletal myoblasts and bone marrow cells in canine hearts for ischemic cardiomyopathy

Osaka University Graduate School of Medicine, Department of Surgery E1, Division of Cardiovascular Surgery, Osaka, Japan

Received for publication August 17, 2004; revisions received January 4, 2005; accepted for publication February 4, 2005.

^_* Address for reprints: Hikaru Matsuda, MD, Osaka University Graduate School of Medicine, Department of Surgery E1, Division of Cardiovascular Surgery, 2-2 Yamada-oka, Suita, Osaka, Japan (Email: memon{at}surg1.med.osaka-u.ac.jp).

OBJECTIVES: Cellular cardiomyoplasty with isolated skeletal myoblasts and bone marrow mononuclear cells is an encouraging therapeutic strategy for heart failure. We investigated the achievements accomplished with combined cell therapy of skeletal myoblast and bone marrow mononuclear cell transplantation to the ischemic canine myocardium.

METHODS: Autologous skeletal myoblasts (1 x 10⁸) and autologous bone marrow mononuclear cells (3 x 10⁶) were injected directly into the damaged myocardium of canine hearts that had undergone 2 weeks of left anterior descending coronary artery ligation. Treatment groups were as follows: skeletal myoblasts plus bone marrow mononuclear cells (combined cell therapy, n = 4), myoblasts (n = 4), bone marrow mononuclear cells (n = 4), and medium only (n = 4). In similarly designed supporting experiments, angiogenic factor expression was evaluated by enzyme-linked immunosorbent assay after cell transplantation in rat hearts that had undergone left anterior descending coronary artery ligation.

RESULTS: Four weeks after cell implantation, echocardiography demonstrated better cardiac performance with reduced left ventricular dilation and significantly improved ejection fraction in the combined cell therapy group compared with that seen in the other groups (pretreatment, 37.7% ± 1.1%, vs combined cell therapy, 55.4% ± 8.6%; myoblasts, 47.4% ± 7.4%; bone marrow mononuclear cells, 44.4% ± 6.7%; medium only [control], 34.4% ± 5.4%; P < .05). A significantly high number of neovessels were observed in the group receiving combined cell therapy only (combined cell therapy, 45.5 ± 12 x 10²/mm²; myoblasts, 26.5 ± 8 x 10²/mm²; bone marrow mononuclear cells, 30.7 ± 15 x 10²/mm²; medium only [control], 7.1 ± 1 x 10²/mm²; P < .05). Immunostained sections expressed the skeletal specific marker myosin heavy chain, although they did not express the cardiac specific marker troponin T. Results of enzyme-linked immunosorbent assay showed the highest expression of vascular endothelial growth factor (combined cell therapy, 2.9 ± 0.7 ng/g tissue; myoblasts, 0.24 ± 0.7 ng/g tissue; bone marrow mononuclear cells, 1.9 ± 0.2 ng/g tissue; medium only [control], 0.19 ± 0.004 ng/g tissue; P < .05) and hepatocyte growth factor in the combined cell therapy hearts.

CONCLUSIONS: Combined autologous cellular therapy induced both myogenesis and angiogenesis with enhancement of cardiac performance and reduction of cardiac remodeling, suggesting a capable strategy for treating severe ischemic cardiomyopathy clinically.

This article has been cited by other articles:

				N. Dib, J. Dinsmore, Z. Lababidi, B. White, S. Moravec, A. Campbell, A. Rosenbaum, K. Seyedmadani, W. A. Jaber, C. S. Rizenhour, et al. One-Year Follow-Up of Feasibility and Safety of the First U.S., Randomized, Controlled Study Using 3-Dimensional Guided Catheter-Based Delivery of Autologous Skeletal Myoblasts for Ischemic Cardiomyopathy (CAuSMIC Study) J. Am. Coll. Cardiol. Intv., January 1, 2009; 2(1): 9 - 16. [Abstract] [Full Text] [PDF]

				N. Bonaros, R. Rauf, E. Werner, B. Schlechta, E. Rohde, A. Kocher, J. Bonatti, and G. Laufer Neoangiogenesis after combined transplantation of skeletal myoblasts and angiopoietic progenitors leads to increased cell engraftment and lower apoptosis rates in ischemic heart failure Interactive CardioVascular and Thoracic Surgery, April 1, 2008; 7(2): 249 - 255. [Abstract] [Full Text] [PDF]

				R. Martinez-Marmol, M. David, R. Sanches, M. Roura-Ferrer, N. Villalonga, E. Sorianello, S. M. Webb, A. Zorzano, A. Guma, C. Valenzuela, et al. Voltage-dependent Na+ channel phenotype changes in myoblasts. Consequences for cardiac repair Cardiovasc Res, December 1, 2007; 76(3): 430 - 441. [Abstract] [Full Text] [PDF]

				N. Bonaros, R. Rauf, D. Wolf, E. Margreiter, A. Tzankov, B. Schlechta, A. Kocher, H. Ott, T. Schachner, S. Hering, et al. Combined transplantation of skeletal myoblasts and angiopoietic progenitor cells reduces infarct size and apoptosis and improves cardiac function in chronic ischemic heart failure J. Thorac. Cardiovasc. Surg., December 1, 2006; 132(6): 1321 - 1328. [Abstract] [Full Text] [PDF]

				H. C. Ott, J. Brechtken, C. Swingen, T. M. Feldberg, T. S. Matthiesen, S. A. Barnes, W. Nelson, and D. A. Taylor Robotic minimally invasive cell transplantation for heart failure J. Thorac. Cardiovasc. Surg., July 1, 2006; 132(1): 170 - 173. [Full Text] [PDF]